FDA “Critical Path” May Lead To Changes In Dosing, Active-Control Trials
Executive Summary
FDA's "Critical Path" drug development initiative will explore relaxing the agency's interpretation of active-control trials, Office of Medical Policy Director Robert Temple, MD, said